MedCity News
FEBRUARY 19, 2024
From diagnostics to treatment methodologies, BCI technology can unravel new dimensions of understanding and intervention, fundamentally altering the landscape of patient care.
pharmaphorum
FEBRUARY 19, 2024
Fast approaching the end of its patent life, Roche and Novartis’ Xolair is going out with a bang, picking up a new approval as the first and only drug therapy for people with food allergies in the US.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MedCity News
FEBRUARY 19, 2024
HHS recently released a final rule that allows practitioners in Opioid Treatment Programs to start patients on methadone or buprenorphine via telehealth. However, the final rule does not apply to the broader range of providers, leading telehealth advocates to call for additional changes from the DEA.
pharmaphorum
FEBRUARY 19, 2024
AstraZeneca’s Tagrisso is cleared by FDA for use alongside chemotherapy as a frontline therapy for EGFR-positive lung cancer (NSCLC)
Advertisement
What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.
MedCity News
FEBRUARY 19, 2024
In this episode, we’re joined by Régine Sitruk-Ware, a distinguished scientist at the Population Council’s Center for Biomedical Research (CBR), and Chelsea Polis, senior scientist of epidemiology at CBR. They talk about the effect upcoming male birth control products could have on women’s health.
Copyright Clearance Center
FEBRUARY 19, 2024
For nearly half a century, the Journal Citation Reports, or JCR, have been “must reading” in universities around the world. Dr. Nandita Quaderi, a senior vice president and the editor in chief for Web of Science at Clarivate, shares the latest developments in the JCR’s ongoing evolution.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
European Pharmaceutical Review
FEBRUARY 19, 2024
The World Health Organization (WHO) has launched a new Biomanufacturing Workforce Training Initiative to help overcome challenges within the biomanufacturing sector in low- and middle-income countries’ (LMICs). The programme aims to support the limited capacity within the industry in LMICs. Another goal of the initiative is to manage the shortage of a qualified workforce in the production of biological products, such as vaccines, and monoclonal antibodies (mAbs).
MedCity News
FEBRUARY 19, 2024
During a recent panel, three health system executives shared some of the most important lessons they’ve learned from the digital initiatives they’ve worked on in the past couple years. Some of their nuggets of wisdom included starting with a problem instead of a solution and being sure not to use financial ROI as the only metric for success.
European Pharmaceutical Review
FEBRUARY 19, 2024
Amtagvi (lifileucel) is the first tumour-derived autologous T cell immunotherapy therapy to be approved by the US Food and Drug Administration (FDA) for certain adults with unresectable or metastatic melanoma” Amtagvi (lifileucel) is the first tumour-derived autologous T cell immunotherapy therapy to be approved by the US Food and Drug Administration (FDA) for certain adults with unresectable or metastatic melanoma.
Pharmaceutical Technology
FEBRUARY 19, 2024
Almirall has signed a licensing agreement for the acquisition of worldwide rights to Novo Nordisk’s IL21-hindering antibody NN-8828.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
PharmaTimes
FEBRUARY 19, 2024
Participants who received COMPASS showed a clinically significant improvement after 12 weeks
Pharmaceutical Technology
FEBRUARY 19, 2024
DYNE-251 is an antisense oligonucleotide commercialized by Dyne Therapeutics, with a leading Phase II program in Duchenne Muscular Dystrophy.
PharmaTimes
FEBRUARY 19, 2024
The study aims to improve the representation of ethnic diversity within Parkinson’s research
pharmaphorum
FEBRUARY 19, 2024
FDA sets December date for decision on AstraZeneca and Daiichi Sankyo’s TROP2-directed ADC Dato-DXd as a therapy for lung cancer (NSCLC)
Advertisement
Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten
Pharmaceutical Commerce
FEBRUARY 19, 2024
Tagrisso (osimertinib) approved for use in combination with platinum-based chemotherapy in adults with locally advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer harboring EGFR exon 19 deletions or exon 21 L858R mutations.
PharmExec
FEBRUARY 19, 2024
The FDA has also approved Tagrisso (osimertinib) as a monotherapy for the first-line treatment of patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC), locally advanced or metastatic EGFR T790M mutation-positive NSCLC, and adjuvant treatment of early-stage EGFRm NSCLC.
Pharmacy Times
FEBRUARY 19, 2024
California's Stop Dangerous Pharmacies Act aims to improve patient safety by establishing new pharmacy staffing regulations and a medication error reporting system, arising from understaffed conditions.
Pharmaceutical Commerce
FEBRUARY 19, 2024
The partnership revolves around meeting various agency standards and industry requirements pertaining to the drug development and manufacturing lifecycle.
PharmExec
FEBRUARY 19, 2024
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Pharmaceutical Technology
FEBRUARY 19, 2024
Iovance Biotherapeutics' Amtagvi has received accelerated US FDA approval for treating adults with metastatic or unresectable melanoma.
Pharmacy Times
FEBRUARY 19, 2024
The full scope of pharmacy practice offers a transformative approach to health care delivery, promising improved patient outcomes, greater access to care, and efficient utilization of health care resources.
Pharmaceutical Technology
FEBRUARY 19, 2024
The US Food and Drug Administration (FDA) has requested a partial clinical hold on all solid tumour trials for Gilead's magrolimab.
Advertisement
Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.
Pharmaceutical Commerce
FEBRUARY 19, 2024
Iovance’s Amtagvi (lifileucel) gains FDA accelerated approval for adults with unresectable or metastatic melanoma.
Pharmaceutical Technology
FEBRUARY 19, 2024
The US FDA has granted approval for AstraZeneca's Tagrisso regimen for EGFRm non-small cell lung cancer (NSCLC) in adults.
Pharmaceutical Commerce
FEBRUARY 19, 2024
The lack of transparency in the pharmaceutical industry further exacerbates the challenges faced by consumers.
Pharmaceutical Technology
FEBRUARY 19, 2024
Applied plans to submit a new drug application following the announcement of positive interim data from its Phase III trial.
Pharmacy Times
FEBRUARY 19, 2024
Matthew Pianko, MD, outlines the logistical considerations involved when implementing bispecific antibodies for the treatment of multiple myeloma, including the roles of the project champion and other stakeholders as part of a multidisciplinary team.
Pharmaceutical Technology
FEBRUARY 19, 2024
An FDA approval in late 2024 would make it the first TROP2-directed therapy for NSCLC antibody drug conjugate patients.
Pharmaceutical Commerce
FEBRUARY 19, 2024
The new seals include sustainable film material containing recyclate content of up to 90%.
Pharmaceutical Technology
FEBRUARY 19, 2024
Pembrolizumab is under clinical development by Merck and currently in Phase II for Myxoid Liposarcoma.
Advertisement
Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A
Expert insights. Personalized for you.
128 
Let's personalize your content